Table 1.
Baseline Demographics and HIV-Related Factors by Randomization Group
| Rosuvastatin (n=72) | Placebo (n=75) | |
|---|---|---|
|
| ||
| Age, years | 45 ± 9 | 45 ± 11 |
| Male | 58 (81) | 57 (76) |
| African American Race | 50 (69) | 50 (67) |
| Body Mass Index, kg/mm2 | 28 ± 6.3 | 28.1 ± 6.7 |
|
| ||
| Hemoglobin A1C, % | 5.5 ± 0.4 | 5.5 ± 0.5 |
| HOMA-IR | 2.74 ± 3.79 | 3.87 ± 4.75 |
| Non HDL cholesterol, mg/dL | 118.3 ± 29.9 | 128.6 ± 29.0 |
| HDL cholesterol, mg/dL | 48.6 ± 16.4 | 48.7 ± 15.4 |
| Triglycerides, mg/dL | 155.4 ± 129.2 | 147.6 ± 88.4 |
| AST (U/dL) | 26.25 ± 26.1 | 23.26 ± 12.0 |
| ALT (U/dL) | 37.3 ± 25.9 | 36.5 ± 19.5 |
| Metabolic Syndrome | 16 (22) | 16 (21) |
|
| ||
| CD4+ cell count, cells/mm2 | 644 ± 287 | 636 ± 314 |
| Nadir CD4+ count, cells/mm2 | 210 ± 155 | 192 ± 137 |
| HIV-1 RNA ≤ 49 copies/ml | 55 (76) | 57 (76) |
| ART duration, years | 7.0 ± 5.3 | 7.3 ± 5.2 |
| Didanosine, stavudine, or zidovudine use | ||
| Current | 5(7) | 3(4) |
| Past | 34(47) | 35(47) |
| Uncertain past exposure | 10(14) | 16(21) |
|
| ||
| Excessive alcohol use | 3(4) | 1(1) |
| Hepatitis C co-infection | 5 (7) | 7 (9) |
| Hepatitis B co-infection | 3 (4) | 4 (5) |
| Liver Fat Score | −0.4 ± 2.6 | 0.2 ± 2.9 |
| NAFLD-Fibrosis Score | −2.4 ± 1.1 | −2.5 ± 1.3 |
| Liver Fat Score > 1.257 | 9 (13) | 21 (28) |
| NAFLD-Fibrosis Score > 0.676 | 1(1) | 0 |
Mean ± standard deviation and frequency (%).
HOMA-IR, homeostatic model assessment of insulin resistance; ART, antiretroviral therapy; NAFLD, nonalcoholic fatty liver disease